• 1
    WHO. The Treatment of Diarrhea. A Manual for Physicians and other Senior Health Workers; WHO/CDR/95.3. Geneva: World Health Organization, 1995.
  • 2
    Riedel BD, Ghishan FK. Acute diarrhea. In: WalkerWA, DuriePR, HamiltonJR, Walker-SmithJA, WatkinsJB, eds. Pediatric Gastrointestinal Disease, 2nd edn. St Louis: Mosby-Year Book Inc., 1996: 25162.
  • 3
    Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998; 39: 2378.
  • 4
    Van Niel C, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002; 109: 67884.
  • 5
    Huang JS, Bousvaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002; 47: 262534.
  • 6
    Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2003 (issue 4). Art. No.: CD003048.pub2. DOI: 10.1002/14651858.CD003048.pub2.
  • 7
    Szajewska H, Mrukowicz J. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo controlled trials. J Pediatr Gastroenterol Nutr 2001; 33: S1725.
  • 8
    Rodrigues AC, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 1996; 81: 2516.
  • 9
    Czerucka D, Rampal P. Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl- secretion in T84 cells. Dig Dis Sci 1999; 44: 235968.
  • 10
    Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun 2001; 69: 1298305.
  • 11
    Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 110815.
  • 12
    Brandao RL, Castro IM, Bambirra EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 1998; 64: 5648.
  • 13
    Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulin in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 2516.
  • 14
    Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 27625.
  • 15
    Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343: 6976.
  • 16
    Szajewska H, Mrukowicz J. Meta-analysis: Non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic associated diarrhoea. Aliment Pharmacol Ther 2005; 22: 36572.
  • 17
    Hafeez A, Tariq P, Ali S, Kundi ZU, Khan A, Hassan M. The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Physicians Surg Pak 2002; 12: 4324.
  • 18
    Higgins JPT, Green S., editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd, 2005.
  • 19
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 62934.
  • 20
    Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G. Saccharomyces boulardii in acute childhood diarrhea: a randomized controlled study. (In press).
  • 21
    Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006; 12: 455760.
  • 22
    Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 2005; 94: 447.
  • 23
    Cetina-Sauri G, Busto GS. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Ped 1994; 6: 397400.
  • 24
    Chapoy P. Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii. Ann Pediatr (Paris) 1985; 32: 5613 (French).
  • 25
    Urganci N, Polat T, Uysalol M, Cetinkaya F. Evaluation of the efficacy of Saccharomyces boulardii in children with acute diarrhoea. Arch Gastroenterohepatol 2001; 20: 16.
  • 26
    Hochter W, Chase D, Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment. Münch Med Wochen 1990; 132: 18892.
  • 27
    Human Development Report 2004. Available at: (Last accessed October 2006).
  • 28
    World Health Organization. The Rational Use of Drugs in the Management of Acute Diarrhoea in Children. Geneva, Switzerland: World Health Organization, 1990.
  • 29
    Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with S. boulardii. Am J Med 1998; 105: 712.
  • 30
    Rijnders BJA, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26: 825.
  • 31
    Zunic P, Lacotte J, Pegoix M, et al. S. boulardii fungemia. Apropos of a case. Therapie 1991; 46: 4989.